These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36461940)

  • 61. Development and validation of assays for the quantification of β-D-N
    Parsons TL; Kryszak LA; Marzinke MA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Oct; 1182():122921. PubMed ID: 34555541
    [TBL] [Abstract][Full Text] [Related]  

  • 62. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686
    [TBL] [Abstract][Full Text] [Related]  

  • 63. N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody.
    Zibat A; Zhang X; Dickmanns A; Stegmann KM; Dobbelstein AW; Alachram H; Soliwoda R; Salinas G; Groß U; Görlich D; Kschischo M; Wollnik B; Dobbelstein M
    iScience; 2023 Oct; 26(10):107786. PubMed ID: 37731621
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants.
    Teli D; Balar P; Patel K; Sharma A; Chavda V; Vora L
    Metabolites; 2023 Feb; 13(2):. PubMed ID: 36837928
    [TBL] [Abstract][Full Text] [Related]  

  • 65. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
    Atmar RL; Finch N
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
    Parums DV
    Med Sci Monit; 2022 Oct; 28():e938532. PubMed ID: 36181334
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Why Molnupiravir Fails in Hospitalized Patients.
    Brown AN; Lang Y; Zhou J; Franco EJ; Hanrahan KC; Bulitta JB; Drusano GL
    mBio; 2022 Dec; 13(6):e0291622. PubMed ID: 36374076
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity.
    Hadj Hassine I; Ben M'hadheb M; Menéndez-Arias L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458571
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Computational Analysis of Molnupiravir.
    Sharov AV; Burkhanova TM; Taskın Tok T; Babashkina MG; Safin DA
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163429
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients.
    Alteri C; Fox V; Scutari R; Burastero GJ; Volpi S; Faltoni M; Fini V; Granaglia A; Esperti S; Gallerani A; Costabile V; Fontana B; Franceschini E; Meschiari M; Campana A; Bernardi S; Villani A; Bernaschi P; Russo C; Guaraldi G; Mussini C; Perno CF
    Commun Biol; 2022 Dec; 5(1):1376. PubMed ID: 36522489
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Molnupiravir: From Hope to Epic Fail?
    Focosi D
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36423169
    [TBL] [Abstract][Full Text] [Related]  

  • 72. White targeted chromatographic screening method of Molnupiravir and its metabolite with degradation kinetics characterization and in-silico toxicity.
    Aboras SI; Megahed AA; El-Yazbi F; Maher HM
    Sci Rep; 2023 Oct; 13(1):17919. PubMed ID: 37863912
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study.
    Xie Y; Choi T; Al-Aly Z
    BMJ; 2023 Apr; 381():e074572. PubMed ID: 37161995
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of the 5'-Triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir on CTP Synthase Catalysis and Filament Formation: Implications for Repurposing Antiviral Agents against SARS-CoV-2.
    Gillis TD; Bearne SL
    ChemMedChem; 2022 Dec; 17(23):e202200399. PubMed ID: 36184568
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19.
    Kulkarni P; Padmanabhan S
    Biotechnol Lett; 2022 Jul; 44(7):831-843. PubMed ID: 35608787
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance.
    Flisiak R; Zarębska-Michaluk D; Rogalska M; Kryńska JA; Kowalska J; Dutkiewicz E; Dobrowolska K; Jaroszewicz J; Moniuszko-Malinowska A; Rorat M; Podlasin R; Tronina O; Rzymski P
    Pharmacol Rep; 2022 Dec; 74(6):1279-1285. PubMed ID: 36001284
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Site-specific DNA damage and 8-hydroxydeoxyguanosine formation by hydroxylamine and 4-hydroxyaminoquinoline 1-oxide in the presence of Cu(II): role of active oxygen species.
    Yamamoto K; Inoue S; Kawanishi S
    Carcinogenesis; 1993 Jul; 14(7):1397-401. PubMed ID: 8330356
    [TBL] [Abstract][Full Text] [Related]  

  • 78. First-generation oral antivirals against SARS-CoV-2.
    Sendi P; Razonable RR; Nelson SB; Soriano A; Gandhi RT
    Clin Microbiol Infect; 2022 Sep; 28(9):1230-1235. PubMed ID: 35545195
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2.
    Holman W; Holman W; McIntosh S; Painter W; Painter G; Bush J; Cohen O
    Trials; 2021 Aug; 22(1):561. PubMed ID: 34425873
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A phase I, randomized, placebo-controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID-19.
    Nakamura K; Fujimoto K; Hasegawa C; Aoki I; Yoshitsugu H; Ugai H; Yatsuzuka N; Tanaka Y; Furihata K; Maas BM; Wickremasingha PK; Duncan KE; Iwamoto M; Stoch SA; Uemura N
    Clin Transl Sci; 2022 Nov; 15(11):2697-2708. PubMed ID: 36053806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.